SG11202005620QA - THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER - Google Patents
THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKERInfo
- Publication number
- SG11202005620QA SG11202005620QA SG11202005620QA SG11202005620QA SG11202005620QA SG 11202005620Q A SG11202005620Q A SG 11202005620QA SG 11202005620Q A SG11202005620Q A SG 11202005620QA SG 11202005620Q A SG11202005620Q A SG 11202005620QA SG 11202005620Q A SG11202005620Q A SG 11202005620QA
- Authority
- SG
- Singapore
- Prior art keywords
- glaucoma
- blocker
- agonist
- therapeutic agent
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017244573 | 2017-12-21 | ||
PCT/JP2018/047102 WO2019124523A1 (ja) | 2017-12-21 | 2018-12-20 | FP作動薬とβ遮断薬を含有する緑内障治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005620QA true SG11202005620QA (en) | 2020-07-29 |
Family
ID=66993519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005620QA SG11202005620QA (en) | 2017-12-21 | 2018-12-20 | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210085636A1 (zh) |
EP (1) | EP3730137B1 (zh) |
JP (1) | JP7247894B2 (zh) |
KR (1) | KR20200102435A (zh) |
CN (1) | CN111479567B (zh) |
AU (1) | AU2018390274C1 (zh) |
BR (1) | BR112020012521A2 (zh) |
CA (1) | CA3085747A1 (zh) |
EA (1) | EA202091523A1 (zh) |
MX (1) | MX2020006429A (zh) |
PH (1) | PH12020550862A1 (zh) |
SG (1) | SG11202005620QA (zh) |
TW (1) | TWI809021B (zh) |
WO (1) | WO2019124523A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202404569A (zh) * | 2022-04-22 | 2024-02-01 | 日商參天製藥股份有限公司 | 含有賽佩普斯特(Sepetaprost)之眼科用組合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2653468T3 (en) * | 2009-07-28 | 2016-06-06 | Ono Pharmaceutical Co | Bicyclic compound AND USE THEREOF FOR MEDICAL PURPOSES |
-
2018
- 2018-12-20 JP JP2019560578A patent/JP7247894B2/ja active Active
- 2018-12-20 CA CA3085747A patent/CA3085747A1/en active Pending
- 2018-12-20 US US16/954,416 patent/US20210085636A1/en active Pending
- 2018-12-20 TW TW107146169A patent/TWI809021B/zh active
- 2018-12-20 EP EP18891086.3A patent/EP3730137B1/en active Active
- 2018-12-20 WO PCT/JP2018/047102 patent/WO2019124523A1/ja unknown
- 2018-12-20 CN CN201880080852.2A patent/CN111479567B/zh active Active
- 2018-12-20 EA EA202091523A patent/EA202091523A1/ru unknown
- 2018-12-20 BR BR112020012521-0A patent/BR112020012521A2/pt unknown
- 2018-12-20 AU AU2018390274A patent/AU2018390274C1/en active Active
- 2018-12-20 SG SG11202005620QA patent/SG11202005620QA/en unknown
- 2018-12-20 KR KR1020207016945A patent/KR20200102435A/ko not_active Application Discontinuation
- 2018-12-20 MX MX2020006429A patent/MX2020006429A/es unknown
-
2020
- 2020-06-11 PH PH12020550862A patent/PH12020550862A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI809021B (zh) | 2023-07-21 |
US20210085636A1 (en) | 2021-03-25 |
PH12020550862A1 (en) | 2021-05-17 |
EP3730137B1 (en) | 2024-03-20 |
TW201934542A (zh) | 2019-09-01 |
KR20200102435A (ko) | 2020-08-31 |
MX2020006429A (es) | 2020-09-17 |
JPWO2019124523A1 (ja) | 2020-12-10 |
EA202091523A1 (ru) | 2020-09-10 |
CN111479567B (zh) | 2023-05-23 |
WO2019124523A1 (ja) | 2019-06-27 |
BR112020012521A2 (pt) | 2020-11-24 |
CA3085747A1 (en) | 2019-06-27 |
JP7247894B2 (ja) | 2023-03-29 |
EP3730137A4 (en) | 2021-02-24 |
AU2018390274A1 (en) | 2020-07-02 |
EP3730137A1 (en) | 2020-10-28 |
AU2018390274B2 (en) | 2023-02-02 |
AU2018390274C1 (en) | 2024-02-29 |
CN111479567A (zh) | 2020-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283362A (en) | A thrbeta receptor agonist compound and a method for its preparation and use | |
SG10202005315SA (en) | Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist | |
EP3213753A4 (en) | Skin barrier function-improving agent and composition for improving skin barrier function | |
WO2015153514A8 (en) | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists | |
GB2557741B (en) | Icariside compound, preperation method thereof, and application thereof | |
EP3887000A4 (en) | METHOD AND AQUEOUS COMPOSITION FOR PREVENTING FOREST FIRES | |
SG11201803669UA (en) | Microorganism-controlling agent and miticidal composition | |
ZA202002517B (en) | Compounds and methods for reducing snca expression | |
GB2562270B (en) | Skin barrier composition | |
EP3052125A4 (en) | Composition and method for therapeutic agent delivery during pregnancy | |
EP3903775A4 (en) | R-KETAMINE AND ITS DERIVATIVE USEFUL AS A PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST A NEURODEVELOPMENTAL DISORDER | |
FI3248597T3 (fi) | Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen | |
GB2577420B (en) | Glycopeptide derivative compounds and uses thereof | |
EP3395324A4 (en) | ANTI-AGING AGENT AND ANTI-AGING COMPOSITION FOR THE SKIN | |
PT3733177T (pt) | Composição para proteção da córnea | |
ZA201901089B (en) | S1p1 agonist and application thereof | |
EP3573957A4 (en) | SODIUM DUCT BLOCKING COMPOSITIONS AND METHODS | |
SG11202005620QA (en) | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER | |
EP3636266A4 (en) | COMPOSITION FOR INHIBITING SKIN DISEASE AND COMPOSITION FOR INHIBITING SKIN DISEASE | |
EP3708642A4 (en) | INITIAL ENEMY COMPOSITION AND INITIAL ENEMY SYSTEM WITH THIS COMPOSITION | |
EP3570890A4 (en) | PXR AGONISTS AND THEIR USES FOR THE TREATMENT AND PREVENTION OF INTESTINAL BARRIER MALFUNCTION | |
IL258431A (en) | Deimmunized therapeutic compositions and methods | |
IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
EP3342806A4 (en) | METHOD OF MANUFACTURING LIQUID-RESISTANT FORM AND COMPOSITION OF A LIQUID-REPRODUCING MEDIUM | |
HUE059248T2 (hu) | Új, centrálisan aktív ghrelinagonista és gyógyászati alkalmazása |